skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

Journal Publications by PDCMDC Members

Click on the Expand plus sign sign to list the journal publications by year. Then click on the PubMed link for details of that publication.

Time Line

Expand All

2014

Collapse All | Expand All

 

  • Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Reply: Dystonia after severe head injuries. Mov Disord. 2014;:. [view publication]
  • Baizabal-Carvallo JF, Jankovic J. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014;17(1):104-6. [view publication]
  • Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurol. 2014;:. [view publication]
  • Factor SA, Jankovic J. Editorial: neurotherapeutics of movement disorders. Neurotherapeutics. 2014;11(1):3-5. [view publication]
  • Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, et al. Designing clinical trials for dystonia. Neurotherapeutics. 2014;11(1):117-27. [view publication]
  • Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014;:. [view publication]
  • Le W, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics. 2014;11(1):92-110. [view publication]
  • Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, et al. Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(3):274-9. [view publication]
  • Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014;20(2):142-8. [view publication]
  • Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100-12. [view publication]
  • Patel N, Ondo W, Jimenez-Shahed J. Habituation and Rebound to Thalamic Deep Brain Stimulation in Long-Term Management of Tremor Associated with Demyelinating Neuropathy. Int J Neurosci. 2014;:. [view publication]
  • Pulliam CL, Eichenseer SR, Goetz CG, Waln O, Hunter CB, Jankovic J, et al. Continuous in-home monitoring of essential tremor. Parkinsonism Relat Disord. 2014;20(1):37-40. [view publication]
  • Thenganatt MA, Jankovic J. Parkinson Disease Subtypes. JAMA Neurol. 2014;:. [view publication]
  • Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11(1):139-52. [view publication]
  • Virmani T, Thenganatt MA, Goldman JS, Kubisch C, Greene PE, Alcalay RN. Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia. Parkinsonism Relat Disord. 2014;20(2):245-7. [view publication]
  • Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126-30. [view publication]

2013

Collapse All | Expand All

 

  • Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28(7):863-73. [view publication]
  • Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm. 2013;120(11):1579-89. [view publication]
  • Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013;24(2):298-306. [view publication]
  • Baizabal-Carvallo JF, Jankovic J. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2013;:. [view publication]
  • Baizabal-Carvallo JF, Jankovic J. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2013;:. [view publication]
  • Baizabal-Carvallo JF, Kagnoff MN, Jimenez-Shahed J, Fekete R, Jankovic J. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2013;:. [view publication]
  • Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013;28(4):543-7. [view publication]
  • Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritability of tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;9(10):e1003864. [view publication]
  • Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive Epidemiology of Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [view publication]
  • Deng H, Gao K, Jankovic J. The VPS35 gene and Parkinson's disease. Mov Disord. 2013;28(5):569-75. [view publication]
  • Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013;70(1):20-4. [view publication]
  • Dhungana S, Jankovic J. Yips and other movement disorders in golfers. Mov Disord. 2013;28(5):576-81. [view publication]
  • Fernandez HH, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, et al. Prospective study evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm: Interim results from the first 145 subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [view publication]
  • Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [view publication]
  • Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114. [view publication]
  • Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001-12. [view publication]
  • Kansara S, Trivedi A, Chen S, Jankovic J, Le W. Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm. 2013;120(1):197-210. [view publication]
  • Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013;80(22):2022-7. [view publication]
  • Louis ED, Bain PG, Hallett M, Jankovic J, Vonsattel JP. What is It? Difficult to Pigeon Hole Tremor: a Clinical-Pathological Study of a Man with Jaw Tremor. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [view publication]
  • Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210-5. [view publication]
  • Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013;12(6):597-608. [view publication]
  • Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013;328(1-2):1-8. [view publication]
  • Mehanna R, Jankovic J. Restless legs syndrome and cerebrovascular disease - Authors' reply. Lancet Neurol. 2013;12(8):734-5. [view publication]
  • Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141-52. [view publication]
  • Nutt J, Siderowf A, Guttman M, Schmidt P, Zamudio J, Wu S, et al. Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2013;:. [view publication]
  • Patel AJ, Sarwar AI, Jankovic J, Viswanathan A. Bilateral pallidal deep brain stimulation for X-linked dystonia parkinsonism. World Neurosurg. 2013;:. [view publication]
  • Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775-83. [view publication]
  • Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249-66. [view publication]
  • Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, et al. Genome-wide association study of Tourette's syndrome. Mol Psychiatry. 2013;18(6):721-8. [view publication]
  • Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol. 2013;11(1):59-79. [view publication]
  • Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [view publication]
  • Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013;28(5):668-70. [view publication]
  • Strickland BA, Jimenez-Shahed J, Jankovic J, Viswanathan A. Radiofrequency lesioning through deep brain stimulation electrodes: A pilot study of lesion geometry and temperature characteristics. J Clin Neurosci. 2013;20(12):1709-12. [view publication]
  • Truong DD, Gollomp SM, Jankovic J, Lewitt PA, Marx M, Hanschmann A, et al. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin((R))) injections in blepharospasm. J Neural Transm. 2013;120(9):1345-53. [view publication]
  • Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:. [view publication]
  • Waln O, Jankovic J. Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord. 2013;28(8):1162-3. [view publication]
  • Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013;28(12):1748-9. [view publication]
  • Waln O, Jimenez-Shahed J. Rechargeable Deep Brain Stimulation Implantable Pulse Generators in Movement Disorders: Patient Satisfaction and Conversion Parameters. Neuromodulation. 2013;:. [view publication]

2012

Collapse All | Expand All

 

  • Atassi MZ, Jankovic J, Steward LE, Aoki KR, Dolimbek BZ. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012;217(1):17-27. [view publication]
  • Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012;90(5):300-6. [view publication]
  • Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord. 2012;27(8):935-46. [view publication]
  • Baizabal-Carvallo JF, Jankovic J. Spinocerebellar ataxia types 2 and 10: more than a coincidental association? Arch Neurol. 2012;69(11):1524-5. [view publication]
  • Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8(4):203-13. [view publication]
  • Deng H, Gu S, Jankovic J. LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand. 2012;125(1):1-7. [view publication]
  • Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46(1):1-18. [view publication]
  • Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, et al. Reliability of a new scale for essential tremor. Mov Disord. 2012;27(12):1567-9. [view publication]
  • Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: A prospective, open-label extension study. Parkinsonism Relat Disord. 2012;18(5):488-93. [view publication]
  • Fekete R, Baizabal-Carvallo JF, Ha AD, Davidson A, Jankovic J. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012;83(2):202-4. [view publication]
  • Fekete R, Jankovic J. Childhood stiff-person syndrome improved with rituximab. Case Rep Neurol. 2012;4(2):92-6. [view publication]
  • Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, et al. Head injury, alpha-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012;71(1):40-8. [view publication]
  • Guo Y, Deng X, Jankovic J, Su L, Zhang J, Le W, et al. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012;526(2):150-3. [view publication]
  • Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord. 2012;27(4):485-91. [view publication]
  • Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, et al. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2012;11:140. [view publication]
  • Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol. 2012;25(4):433-47. [view publication]
  • Jankovic J. Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012;25(4):429-32. [view publication]
  • Jimenez-Shahed J. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin(R)), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatr Dis Treat. 2012;8:13-25. [view publication]
  • Lee HY, Huang Y, Bruneau N, Roll P, Roberson ED, Hermann M, et al. Mutations in the novel protein PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012;1(1):2-12. [view publication]
  • Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012;27(2):284-8. [view publication]
  • Li XP, Xie WJ, Zhang Z, Kansara S, Jankovic J, Le WD. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals. 2012;20(4):223-36. [view publication]
  • Marshall DF, Strutt AM, Williams AE, Simpson RK, Jankovic J, York MK. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012;19(12):1525-31. [view publication]
  • Mehanna R, Jankovic J. Respiratory disorders associated with dystonia. Mov Disord. 2012;27(14):1816-9. [view publication]
  • Mostile G, Fekete R, Giuffrida JP, Yaltho T, Davidson A, Nicoletti A, et al. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012;18(7):859-63. [view publication]
  • Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012;11(2):140-9. [view publication]
  • Ondo WG, Hunter C, Ferrara JM, Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012;18(5):619-22. [view publication]
  • Ondo WG, Jankovic J, Simpson R, Jimenez-Shahed J. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012;13(9):1202-4. [view publication]
  • Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650-4. [view publication]
  • Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370-84. [view publication]
  • Patel SS, Jankovic J, Hood AJ, Jeter CB, Sereno AB. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012;313(1-2):35-41. [view publication]
  • Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol. 2012;25(4):448-59. [view publication]
  • Squitieri F, Jankovic J. Huntington's disease: how intermediate are intermediate repeat lengths? Mov Disord. 2012;27(14):1714-7. [view publication]
  • Strutt AM, Simpson R, Jankovic J, York MK. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012;19(1):121-7. [view publication]
  • Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep. 2012;12(4):399-409. [view publication]
  • Thenganatt MA, Louis ED. Distinguishing essential tremor from Parkinson's disease: bedside tests and laboratory evaluations. Expert Rev Neurother. 2012;12(6):687-96. [view publication]
  • Thenganatt MA, Louis ED. Personality profile in essential tremor: a case-control study. Parkinsonism Relat Disord. 2012;18(9):1042-4. [view publication]
  • Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012;90(4):213-24. [view publication]
  • Zhang Z, Li X, Xie W, Tuo H, Hintermann S, Jankovic J, et al. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012;11(6):768-73. [view publication]

<2011

Collapse All | Expand All

 

  • Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011;216(7):782-92. [view publication]
  • Baizabal Carvallo JF, Simpson R, Jankovic J. Diagnosis and treatment of complications related to deep brain stimulation hardware. Mov Disord. 2011;26(8):1398-406. [view publication]
  • Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1-7. [view publication]
  • Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN((R)), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-9. [view publication]
  • Deitiker PR, Oshima M, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011;44(3):167-76. [view publication]
  • Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. 2011;26(3):391-8. [view publication]
  • Ferrara J, Stamey W, Strutt AM, Adam OR, Jankovic J. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011;23(2):141-8. [view publication]
  • Guo Y, Jankovic J, Song Z, Yang H, Zheng W, Le W, et al. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011;487(2):174-6. [view publication]
  • Guo Y, Le WD, Jankovic J, Yang HR, Xu HB, Xie WJ, et al. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011;26(9):1729-32. [view publication]
  • Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625-8. [view publication]
  • Ha AD, Jankovic J. An introduction to dyskinesia--the clinical spectrum. Int Rev Neurobiol. 2011;98:1-29. [view publication]
  • Ha AD, Jankovic J. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011;123(5):116-21. [view publication]
  • Ha AD, Jankovic J. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011;26(8):1556-8. [view publication]
  • Heldman DA, Jankovic J, Vaillancourt DE, Prodoehl J, Elble RJ, Giuffrida JP. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011;17(7):537-42. [view publication]
  • Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699-705. [view publication]
  • Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509-23. [view publication]
  • Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521-8. [view publication]
  • Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011;26(6):1149-56. [view publication]
  • Jankovic J, Yeeles K, Katsakou C, Amos T, Morriss R, Rose D, et al. Family caregivers' experiences of involuntary psychiatric hospital admissions of their relatives--a qualitative study. PLoS One. 2011;6(10):e25425. [view publication]
  • Jankovic J. Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry. 2011;82(12):1300-3. [view publication]
  • Kieburtz K, Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord. 2011;26(1):37-44. [view publication]
  • Le W, Nguyen D, Lin XW, Rawal P, Huang M, Ding Y, et al. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2011;32(4):750-3. [view publication]
  • Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm. 2011;118(3):473-7. [view publication]
  • Nopoulos PC, Aylward EH, Ross CA, Mills JA, Langbehn DR, Johnson HJ, et al. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain. 2011;134(Pt 1):137-42. [view publication]
  • Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, et al. Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(2):117-8. [view publication]
  • Ooi WW, Wijemanne S, Thomas CB, Quezado M, Brown CR, Nash TE. Short report: A calcified Taenia solium granuloma associated with recurrent perilesional edema causing refractory seizures: histopathological features. Am J Trop Med Hyg. 2011;85(3):460-3. [view publication]
  • Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011;237(1-2):66-72. [view publication]
  • Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011;240-241:121-8. [view publication]
  • Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. Int J Cancer. 2011;128(10):2251-60. [view publication]
  • Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, et al. Copy number variation in familial Parkinson disease. PLoS One. 2011;6(8):e20988. [view publication]
  • Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147-52. [view publication]
  • Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415-23. [view publication]
  • Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-80. [view publication]
  • Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011;26(5):925-7. [view publication]
  • Thenganatt MA, Frucht SJ. Treatment options for sleep dysfunction in Parkinson's disease. Curr Treat Options Neurol. 2011;13(5):473-87. [view publication]
  • van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011;82(8):892-8. [view publication]
  • Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011;178(4):1509-16. [view publication]
  • Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011;17(5):321-7. [view publication]
  • Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011;68(1):22-30. [view publication]
  • Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011;19(3):163-74. [view publication]
  • Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011;26(2):359-60. [view publication]
  • Yaltho TC, Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord. 2011;26(9):1582-92. [view publication]
  • Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS, Huntington Study Group. Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv Ment Dis. 2010;198(5):334-8. [view publication]
  • Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS, et al. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414-8. [view publication]
  • Deng H, Yang H, Le W, Deng X, Xu H, Xiong W, et al. Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010;392(4):548-50. [view publication]
  • Deng S, Deng H, Le W, Xu H, Yang H, Deng X, et al. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010;468(3):195-7. [view publication]
  • DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010;25(2):232-8. [view publication]
  • Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 2010;75(6):500-7. [view publication]
  • Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B, et al. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010;25(8):1082-6. [view publication]
  • Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord. 2010;16(6):423-6. [view publication]
  • Fekete R, Jankovic J. Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010;25(4):503-4. [view publication]
  • Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(3):315-9. [view publication]
  • Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs. 2010;70(5):561-71. [view publication]
  • Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM, et al. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010;25(9):1190-4. [view publication]
  • Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133(Pt 3):713-26. [view publication]
  • Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010;29(1):79-125. [view publication]
  • Jankovic J, Gelineau-Kattner R, Davidson A. Tourette's syndrome in adults. Mov Disord. 2010;25(13):2171-5. [view publication]
  • Jankovic J, Jimenez-Shahed J, Brown LW. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70-3. [view publication]
  • Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of parkinsonian deformities. Mov Disord. 2010;25(5):527-8. [view publication]
  • Li C, Guo Y, Xie W, Li X, Janokovic J, Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem Res. 2010;35(10):1546-56. [view publication]
  • Lim J, Sanghera MK, Darbin O, Stewart RM, Jankovic J, Simpson R. Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients. Exp Neurol. 2010;224(2):542-4. [view publication]
  • Mehanna R, Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010;16(10):628-38. [view publication]
  • Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010;10(6):893-901. [view publication]
  • Mostile G, Giuffrida JP, Adam OR, Davidson A, Jankovic J. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010;25(12):1938-43. [view publication]
  • Mostile G, Jankovic J. Alcohol in essential tremor and other movement disorders. Mov Disord. 2010;25(14):2274-84. [view publication]
  • Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544-54. [view publication]
  • Okun MS, Lang A, Jankovic J. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010;25(7):961-2; author reply 962-3. [view publication]
  • Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 2010;25(15):2595-603. [view publication]
  • Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, et al. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19(6):606-17. [view publication]
  • Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010;25(12):1801-8. [view publication]
  • Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010;480(1):78-82. [view publication]
  • Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, et al. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet. 2010;11:53. [view publication]
  • Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18-27. [view publication]
  • Tan EK, Peng R, Teo YY, Tan LC, Angeles D, Ho P, et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010;31(5):561-8. [view publication]
  • Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-23. [view publication]
  • Vilarino-Guell C, Wider C, Ross OA, Jasinska-Myga B, Kachergus J, Cobb SA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010;11(4):401-8. [view publication]
  • Wu Y, Li X, Xie W, Jankovic J, Le W, Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010;57(3):198-205. [view publication]
  • Xie W, Li X, Li C, Zhu W, Jankovic J, Le W. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010;115(1):188-99. [view publication]
  • York MK, Wilde E, Simpson R, Jankovic J. Acknowledgement of technological limitations while moving literature forward. J Neurol Sci. 2010;292(1-2):120. [view publication]
  • Zhu W, Li X, Xie W, Luo F, Kaur D, Andersen JK, et al. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010;37(2):307-13. [view publication]
  • Adam OR, Ferrara JM, Aguilar Tabora LG, Nashatizadeh MM, Negoita M, Jankovic J. Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology. 2009;73(10):e50-2. [view publication]
  • Adam OR, Ferrara JM, Jankovic J. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009;24(13):2030-2032. [view publication]
  • Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763-72. [view publication]
  • Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763-72. [view publication]
  • Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol. 2009;256(3):320-32. [view publication]
  • Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009;11(5):293-307. [view publication]
  • Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285(1-2):195-7. [view publication]
  • Frank S, Huntington Study Group/TETRA-HD Investigators. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol. 2009;9:62. [view publication]
  • Freeman RD, Zinner SH, Muller-Vahl KR, Fast DK, Burd LJ, Kano Y, et al. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009;51(3):218-27. [view publication]
  • Guo Y, Jankovic J, Zhu S, Le W, Song Z, Xie W, et al. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009;454(3):209-11. [view publication]
  • Gupta A, Jankovic J. Spinocerebellar ataxia 8: variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009;15(9):621-626. [view publication]
  • Jankovic J, Albanese A, Hallett M. Unique properties of botulinum toxins. Toxicon. 2009;54(5):675. [view publication]
  • Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407-13. [view publication]
  • Jankovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1-2):177-8. [view publication]
  • Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54(5):614-23. [view publication]
  • Jankovic J. Movement disorders. Preface. Neurol Clin. 2009;27(3):ix-x. [view publication]
  • Jankovic J. Peripherally induced movement disorders. Neurol Clin. 2009;27(3):821-32, vii. [view publication]
  • Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8(9):844-56. [view publication]
  • Kloppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, et al. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology. 2009;72(5):426-31. [view publication]
  • Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2009;153B(2):397-408. [view publication]
  • Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009;10:98. [view publication]
  • Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009;15(1):28-35. [view publication]
  • Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, et al. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009;73(5):385-92. [view publication]
  • Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, et al. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord. 2009;24(16):2370-8. [view publication]
  • Mata IF, Hutter CM, Gonzalez-Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C, et al. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009;10(4):347-53. [view publication]
  • Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72(4):310-6. [view publication]
  • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-78. [view publication]
  • Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 2009;164(2):541-51. [view publication]
  • Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology. 2009;73(4):279-86. [view publication]
  • Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593-605. [view publication]
  • Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-70. [view publication]
  • Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2009;82(3-4):201-7. [view publication]
  • Ravina B, Elm J, Camicioli R, Como PG, Marsh L, Jankovic J, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24(9):1306-11. [view publication]
  • Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009;24(14):2081-90. [view publication]
  • Sitburana O, Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009;15(10):758-61. [view publication]
  • Strutt AM, Lai EC, Jankovic J, Atassi F, Soety EM, Levin HS, et al. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009;71(5):551-8. [view publication]
  • Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS. Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage. 2009;47 Suppl 2:T53-7. [view publication]
  • Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009;66(9):1106-13. [view publication]
  • Wijemanne S, Jankovic J. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009;24(4):583-9. [view publication]
  • York MK, Wilde EA, Simpson R, Jankovic J. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009;287(1-2):159-71. [view publication]
  • Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5(2):181-97. [view publication]
  • Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? Postgrad Med J. 2008;84(992):313-7. [view publication]
  • Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008;45(15):3878-88. [view publication]
  • Atassi MZ, Jankovic J, Dolimbek BZ. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;71(13):1040; author reply 1040-1. [view publication]
  • Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb Clin Neurol. 2008;89:461-73. [view publication]
  • Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-60. [view publication]
  • Deng H, Le W, Shahed J, Xie W, Jankovic J. Mutation analysis of the parkin and PINK1 genes in American caucasian early-onset Parkinson disease families. Neurosci Lett. 2008;430(1):18-22. [view publication]
  • Deng H, Le WD, Jankovic J. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008;448(2):180-3. [view publication]
  • Dulay MF, Strutt AM, Levin HS, Jankovic J, Lai EC, Grossman RG, et al. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008;20(3):357-63. [view publication]
  • Erer S, Jankovic J. Adult onset tics after peripheral injury. Parkinsonism Relat Disord. 2008;14(1):75-6. [view publication]
  • Ferrara J, Jankovic J. Psychogenic movement disorders in children. Mov Disord. 2008;23(13):1875-81. [view publication]
  • Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127-33. [view publication]
  • Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70. [view publication]
  • Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008;71(16):1275-82. [view publication]
  • Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65(12):1582-9. [view publication]
  • Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008;4(4):743-57. [view publication]
  • Jankovic J, Ashoori A. Movement disorders in musicians. Mov Disord. 2008;23(14):1957-65. [view publication]
  • Jankovic J. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008;63(3):267-9. [view publication]
  • Jankovic J. Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008;7(1):9-11. [view publication]
  • Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-76. [view publication]
  • Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-84. [view publication]
  • Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115(4):585-591. [view publication]
  • Kenney C, Jankovic J. Reply: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2008;23(12):1793. [view publication]
  • Kenney C, Kuo SH, Jimenez-Shahed J. Tourette's syndrome. Am Fam Physician. 2008;77(5):651-8. [view publication]
  • Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg. 2008;110(2):198-201. [view publication]
  • Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008;23(4):616-9. [view publication]
  • Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, et al. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008;273(1-2):29-33. [view publication]
  • Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008;26 Suppl 1:43-53. [view publication]
  • Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23(15):2194-201. [view publication]
  • Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008;7(2):720-30. [view publication]
  • Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008;131(Pt 8):1969-78. [view publication]
  • Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008;32(1):16-25. [view publication]
  • Pan T, Zhu W, Zhao H, Deng H, Xie W, Jankovic J, et al. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008;1222:222-9. [view publication]
  • Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, et al. Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord. 2008;23(15):2216-23. [view publication]
  • Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-80. [view publication]
  • Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71(7):481-5. [view publication]
  • Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23. [view publication]
  • Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-706. [view publication]
  • Sitburana O, Jankovic J. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008;266(1-2):31-3. [view publication]
  • Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233-40. [view publication]
  • Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008;14(4):253-4. [view publication]
  • Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008;14(2):89-99. [view publication]
  • Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008;14(1):77-80. [view publication]
  • Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008;23(16):2307-11. [view publication]
  • York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79(7):789-95. [view publication]
  • Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-9. [view publication]
  • Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008;105(5):1970-8. [view publication]
  • Adair JC, Cooke N, Jankovic J. Alexia without agraphia in Creutzfeldt-Jakob disease. J Neurol Sci. 2007;263(1-2):208-10. [view publication]
  • Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8. [view publication]
  • Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? J Neurol Neurosurg Psychiatry. 2007;78(11):1171-5. [view publication]
  • Atassi MZ, Dolimbek BZ, Deitiker P, Jankovic J, Aoki KR. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007;20(1):15-21. [view publication]
  • Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007;22(12):1743-50. [view publication]
  • Deng H, Le W, Huang M, Xie W, Pan T, Jankovic J. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007;419(2):104-7. [view publication]
  • Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007;130(Pt 6):1456-64. [view publication]
  • Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007;64(3):421-4. [view publication]
  • Diamond A, Kenney C, Almaguer M, Jankovic J. Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. J Neurosurg. 2007;107(5):1036-8. [view publication]
  • Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007;260(1-2):199-203. [view publication]
  • Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44(5):1029-41. [view publication]
  • Erer S, Jankovic J. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007;109(9):784-5. [view publication]
  • Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22(2):179-86. [view publication]
  • Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-7. [view publication]
  • Hauser RA, Salin L, Juhel N, Konyago VL, NS 2330 Monotherapy PD Study Group. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007;22(3):359-65. [view publication]
  • Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69(15):1542-50. [view publication]
  • Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22(1):55-61. [view publication]
  • Jankovic J, Deng H. Candidate locus for chorea and tic disorders at 15q? Pediatr Neurol. 2007;37(1):70-3. [view publication]
  • Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92. [view publication]
  • Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13(7):411-6. [view publication]
  • Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676-82. [view publication]
  • Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain. 2007;130(Pt 7):1732-44. [view publication]
  • Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007;263(1-2):94-9. [view publication]
  • Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22(1):10-3. [view publication]
  • Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-7. [view publication]
  • Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007;8(9):1329-35. [view publication]
  • Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007;22(1):127-30. [view publication]
  • Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106(4):621-5. [view publication]
  • Langbehn DR, Paulsen JS, Huntington Study Group. Predictors of diagnosis in Huntington disease. Neurology. 2007;68(20):1710-7. [view publication]
  • LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30(5):256-65. [view publication]
  • LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262-7. [view publication]
  • May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007;22(16):2371-7. [view publication]
  • Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, et al. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology. 2007;69(18):1737-44. [view publication]
  • Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Mov Disord. 2007;22(2):254-7. [view publication]
  • NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-8. [view publication]
  • Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13(7):453-4. [view publication]
  • Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007;22(4):546-9. [view publication]
  • Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69(15):1480-90. [view publication]
  • Poysky J, Jimenez-Shahed J. Reply: Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2007;22(9):1366-7. [view publication]
  • Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342-7. [view publication]
  • Roessner V, Becker A, Banaschewski T, Freeman RD, Rothenberger A, Tourette Syndrome International Database Consortium. Developmental psychopathology of children and adolescents with Tourette syndrome--impact of ADHD. Eur Child Adolesc Psychiatry. 2007;16 Suppl 1:24-35. [view publication]
  • Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007;13(2):67-76. [view publication]
  • Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007;68(2):159-60. [view publication]
  • Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007;7(6):637-47. [view publication]
  • Stamey W, Jankovic J. The other Babinski sign in hemifacial spasm. Neurology. 2007;69(4):402-4. [view publication]
  • Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252(2):113-20. [view publication]
  • Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272-6. [view publication]
  • Wijemanne S, Jankovic J. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007;69(16):1585-94. [view publication]
  • York MK, Lai EC, Jankovic J, Macias A, Atassi F, Levin HS, et al. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007;149(9):857-66; discussion 866. [view publication]
  • Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J. 2007;21(14):3835-44. [view publication]
  • Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293-348. [view publication]
  • Alibhoy AT, Wijemanne S, Gamage R. Paroxysmal kinesigenic dyskinesia. Ceylon Med J. 2006;51(1):36-7. [view publication]
  • Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;21(11):1856-63. [view publication]
  • Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21(9):1500-2. [view publication]
  • Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006;494(3):495-514. [view publication]
  • Collins A, Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006;67(6):1083-5. [view publication]
  • Deng H, Le W, Davidson AL, Xie W, Jankovic J. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006;407(2):97-100. [view publication]
  • Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006;251(1-2):102-6. [view publication]
  • Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006;63(2):273-7. [view publication]
  • Deng H, Le WD, Xie WJ, Jankovic J. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006;114(6):400-2. [view publication]
  • Deng H, Xie W, Guo Y, Le W, Jankovic J. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006;21(5):728-9. [view publication]
  • Deng H, Xie WJ, Le WD, Huang MS, Jankovic J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006;401(1-2):16-9. [view publication]
  • Diamond A, Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006;5(2):169. [view publication]
  • Diamond A, Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006;6(8):1181-97. [view publication]
  • Diamond A, Kenney C, Jankovic J. Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006;21(8):1273-5. [view publication]
  • Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006;21(5):692-5. [view publication]
  • Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R, et al. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. Brain. 2006;129(Pt 10):2660-6. [view publication]
  • Elble RJ, Tremor Research Group. Report from a U.S. conference on essential tremor. Mov Disord. 2006;21(12):2052-61. [view publication]
  • Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006;21(3):306-9. [view publication]
  • Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol. 2006;63(7):991-6. [view publication]
  • Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-72. [view publication]
  • Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67(12):2233-5. [view publication]
  • Jankovic J, Kwak C, Frankoff R. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006;18(1):86-95. [view publication]
  • Jankovic J, Mejia NI. Tics associated with other disorders. Adv Neurol. 2006;99:61-8. [view publication]
  • Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr. 2006;11(7):501-8. [view publication]
  • Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006;73(4):682-9. [view publication]
  • Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9(2-3):145-8. [view publication]
  • Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864-72. [view publication]
  • Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006;103(28):10753-8. [view publication]
  • Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259-64. [view publication]
  • Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6(1):7-17. [view publication]
  • Kim SJ, Prasad GV, Huang M, Nash MM, Famure O, Park J, et al. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. Transplantation. 2006;82(7):924-30. [view publication]
  • Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, et al. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006;21(11):1831-8. [view publication]
  • Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66(5):672-7. [view publication]
  • Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006;21(8):1252-4. [view publication]
  • Pahwa R, Lyons KE, Wilkinson SB, Simpson RK, Jr, Ondo WG, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104(4):506-12. [view publication]
  • Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, et al. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. Mov Disord. 2006;21(12):2257-60. [view publication]
  • Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, et al. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett. 2006;408(3):209-13. [view publication]
  • Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138-48. [view publication]
  • Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006;63(6):883-90. [view publication]
  • Scahill L, Erenberg G, Berlin CM, Jr, Budman C, Coffey BJ, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192-206. [view publication]
  • Shatunov A, Sambuughin N, Jankovic J, Elble R, Lee HS, Singleton AB, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006;129(Pt 9):2318-31. [view publication]
  • Tan EK, Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol. 2006;63(9):1232-7. [view publication]
  • Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12(6):382-7. [view publication]
  • Wu LJ, Jankovic J. Runner's dystonia. J Neurol Sci. 2006;251(1-2):73-6. [view publication]
  • Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005;4(7):423-31. [view publication]
  • Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65(3):355-9. [view publication]
  • Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-9. [view publication]
  • Deng H, Jankovic J, Guo Y, Xie W, Le W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 2005;337(4):1133-8. [view publication]
  • Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005;57(6):933-4. [view publication]
  • Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005;65(4):651-2. [view publication]
  • Deng H, Le WD, Xie WJ, Pan TH, Zhang X, Jankovic J. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005;382(3):297-9. [view publication]
  • Deng H, Le WD, Zhang X, Pan TH, Jankovic J. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005;111(6):351-2. [view publication]
  • Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005;76(9):1188-93. [view publication]
  • Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;64(3):417-21. [view publication]
  • Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005;20(3):293-7. [view publication]
  • Imam SZ, Jankovic J, Ali SF, Skinner JT, Xie W, Conneely OM, et al. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. Faseb J. 2005;19(11):1441-50. [view publication]
  • Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005;77(1-2):128-38. [view publication]
  • Jankovic J, Noebels JL. Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005;115(3):584-6. [view publication]
  • Jankovic J. Dystonia and other deformities in Parkinson's disease. J Neurol Sci. 2005;239(1):1-3. [view publication]
  • Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20 Suppl 11:S11-6. [view publication]
  • Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005;62(3):351-2. [view publication]
  • Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005;64(12):2021-8. [view publication]
  • Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005;191(1):154-62. [view publication]
  • Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D, SELECT-TC Study Group. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. 2005;112(2):221-30. [view publication]
  • Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20(1):86-9. [view publication]
  • Mejia NI, Jankovic J. Secondary tics and tourettism. Rev Bras Psiquiatr. 2005;27(1):11-7. [view publication]
  • Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592-7. [view publication]
  • Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005;20 Suppl 11:S3-10. [view publication]
  • Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-9. [view publication]
  • Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005;579(30):6716-20. [view publication]
  • Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005;377(2):106-9. [view publication]
  • Paulsen JS, Hoth KF, Nehl C, Stierman L, Huntington Study Group. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005;162(4):725-31. [view publication]
  • Ross S, Jankovic J. Palatal myoclonus: an unusual presentation. Mov Disord. 2005;20(9):1200-3. [view publication]
  • Shatunov A, Jankovic J, Elble R, Sambuughin N, Singleton A, Hallett M, et al. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;65(12):1995; author reply 1995. [view publication]
  • Silay YS, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005;10(2):365-80. [view publication]
  • Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65(5):765-7. [view publication]
  • Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005;62(8):1290-5. [view publication]
  • Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783-91. [view publication]
  • Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005;20(1):44-7. [view publication]
  • Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004;63(6):1096-8. [view publication]
  • Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology. 2004;63(12):2280-7. [view publication]
  • de Carvalho Aguiar P, Fazzari M, Jankovic J, Ozelius LJ. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004;19(10):1237-8. [view publication]
  • Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. Jama. 2004;292(14):1685-6. [view publication]
  • Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-508. [view publication]
  • Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP. Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor. Clin Genet. 2004;66(4):353-7. [view publication]
  • Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53. [view publication]
  • Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27(5):234-44. [view publication]
  • Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics. 2004;114(5):1203-5. [view publication]
  • Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75(7):951-7. [view publication]
  • Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004;94:275-86. [view publication]
  • Jankovic J. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004;63(8):1541-2; author reply 1541-2. [view publication]
  • Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19 Suppl 8:S109-15. [view publication]
  • Jiang C, Wan X, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, et al. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004;27(2):63-73. [view publication]
  • Lassinger BK, Kwak C, Walford RL, Jankovic J. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004;19(4):465-9. [view publication]
  • Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62(11):2005-9. [view publication]
  • Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-90. [view publication]
  • Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, et al. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord. 2004;19(6):649-55. [view publication]
  • Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61(10):1563-8. [view publication]
  • Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62(1):37-40. [view publication]
  • Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27(6):274-7. [view publication]
  • Pan T, Le W, Jankovic J. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004;62(2):343; author reply 343-4. [view publication]
  • Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology. 2004;62(9):1616-8. [view publication]
  • Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004;94:29-36. [view publication]
  • Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004;219(1-2):63-9. [view publication]
  • Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004;19(6):692-5. [view publication]
  • Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004;19(1):36-42. [view publication]
  • Thomas M, Jankovic J, Suteerawattananon M, Wankadia S, Caroline KS, Vuong KD, et al. Clinical Gait and Balance Scale (GABS): validation and utilization. J Neurol Sci. 2004;217(1):89-99. [view publication]
  • Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004;17(4):437-42. [view publication]
  • Thomas M, Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs. 2004;18(7):437-52. [view publication]
  • Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60(5):796-801. [view publication]
  • Frampton JE, Easthope SE. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4(10):709-25. [view publication]
  • Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK, Jr, et al. Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial. Neurology. 2003;61(10):1401-5. [view publication]
  • He Y, Imam SZ, Dong Z, Jankovic J, Ali SF, Appel SH, et al. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003;86(6):1338-45. [view publication]
  • Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, et al. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003;4(4):185-9. [view publication]
  • Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003;18(10):1190-2. [view publication]
  • Hou JG, Jankovic J. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003;206(1):59-64. [view publication]
  • Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-8. [view publication]
  • Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med. 2003;349(1):96-7. [view publication]
  • Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003;18(12):1530-3. [view publication]
  • Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003;60(11):1595-8. [view publication]
  • Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003;33(1):85-9. [view publication]
  • Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12(24):3259-67. [view publication]
  • Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003;10(1):68-79. [view publication]
  • Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, et al. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26(7):461-81. [view publication]
  • Mahant N, McCusker EA, Byth K, Graham S, Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61(8):1085-92. [view publication]
  • Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69-73. [view publication]
  • Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003;60(7):975-80. [view publication]
  • Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003;18(6):683-5. [view publication]
  • Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology. 2003;61(8):1093-7. [view publication]
  • Pan T, Fei J, Zhou X, Jankovic J, Le W. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003;72(9):1073-83. [view publication]
  • Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003;20(10):711-21. [view publication]
  • Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12(20):2599-608. [view publication]
  • Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003;72(4):1053-7. [view publication]
  • Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003;60(12):1721-8. [view publication]
  • Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T, et al. Reliability of reported age at onset for Parkinson's disease. Mov Disord. 2003;18(3):275-9. [view publication]
  • Rosa AL, Jankovic J, Ashizawa T. Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. Arch Neurol. 2003;60(4):502-3. [view publication]
  • Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003;114(2):288-94. [view publication]
  • Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003;52(6):1358-70; discussion 1370-3. [view publication]
  • Savant CS, Singhal BS, Jankovic J, Khan M, Virani A. Substantia nigra lesions in viral encephalitis. Mov Disord. 2003;18(2):213-6. [view publication]
  • Simon DK, Friedman J, Breakefield XO, Jankovic J, Brin MF, Provias J, et al. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003;4(4):199-205. [view publication]
  • Simpkins N, Jankovic J. Neuroprotection in Parkinson disease. Arch Intern Med. 2003;163(14):1650-4. [view publication]
  • Thomas M, Le WD, Jankovic J. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003;26(1):18-23. [view publication]
  • Tintner R, Jankovic J. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003;12(11):1803-20. [view publication]
  • van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003;60(7):1189-91. [view publication]
  • van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003;72(4):804-11. [view publication]
  • Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003;18(12):1527-30. [view publication]
  • Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60(6):998-1001. [view publication]
  • Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002;89:401-20. [view publication]
  • Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord. 2002;17(4):726-34. [view publication]
  • Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002;31(3-4):247-62. [view publication]
  • Jankovic J, Demirkiran M. Classification of paroxysmal dyskinesias and ataxias. Adv Neurol. 2002;89:387-400. [view publication]
  • Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8(4):271-6. [view publication]
  • Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord. 2002;17(4):638-44. [view publication]
  • Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(4 Suppl 1):S19-32. [view publication]
  • Krauss JK, Jankovic J. Head injury and posttraumatic movement disorders. Neurosurgery. 2002;50(5):927-39; discussion 939-40. [view publication]
  • Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002;17(4):821-5. [view publication]
  • Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70(4):985-93. [view publication]
  • Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, et al. Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families. J Med Genet. 2002;39(7):489-92. [view publication]
  • Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031-5. [view publication]
  • Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300-2. [view publication]
  • Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-4. [view publication]
  • Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002;17(2):339-45. [view publication]
  • Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1):124-35. [view publication]
  • Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama. 2002;287(13):1653-61. [view publication]
  • Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341-6. [view publication]
  • Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002;19(3):245-51. [view publication]
  • Sabbahi M, Etnyre B, Al-Jawayed IA, Hasson S, Jankovic J. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002;19(1):67-72. [view publication]
  • Sethi KD, Jankovic J. Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002;17(1):150-3. [view publication]
  • Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51(5):604-12. [view publication]
  • Tintner R, Jankovic J. Treatment options for Parkinson's disease. Curr Opin Neurol. 2002;15(4):467-76. [view publication]
  • Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58(6):881-4. [view publication]
  • Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-63. [view publication]
  • Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001;56(12):1712-21. [view publication]
  • Hanna PA, Ratkos L, Ondo WG, Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm. 2001;108(1):63-70. [view publication]
  • Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord. 2001;16(6):1201-2. [view publication]
  • Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-5. [view publication]
  • Jankovic J, Lai EC, Ondo WG, Roberts-Warrior D, Olson SL, Krauss JK, et al. Effects of pallidotomy on gait and balance. Adv Neurol. 2001;87:271-81. [view publication]
  • Jankovic J, Nutt JG, Sudarsky L. Classification, diagnosis, and etiology of gait disorders. Adv Neurol. 2001;87:119-33. [view publication]
  • Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8(2):109-21. [view publication]
  • Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001;16(1):7-12. [view publication]
  • Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol. 2001;85:15-29. [view publication]
  • Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001;24(11):1568-70. [view publication]
  • Jankovic J. Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001;114(3):227-34. [view publication]
  • Jankovic J. Parkinson's disease. A half century of progress. Neurology. 2001;57(10 Suppl 3):S1-3. [view publication]
  • Jankovic J. Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001;58(12):1970-2. [view publication]
  • Jankovic J. Tourette's syndrome. N Engl J Med. 2001;345(16):1184-92. [view publication]
  • Krauss JK, Simpson RK, Jr, Ondo WG, Pohle T, Burgunder JM, et al. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001;48(3):535-41; discussion 541-3. [view publication]
  • Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18(6):389-96. [view publication]
  • Leckman JF, Cohen DJ, Goetz CG, Jankovic J. Tourette syndrome: pieces of the puzzle. Adv Neurol. 2001;85:369-90. [view publication]
  • Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 2001;3(3):133-43. [view publication]
  • Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. Jama. 2001;286(18):2245-50. [view publication]
  • Ondo W, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001;58(2):218-22. [view publication]
  • Ondo W, Dat Vuong K, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001;16(6):1137-42. [view publication]
  • Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57(8):1392-6. [view publication]
  • Sambuughin N, Nelson TE, Jankovic J, Xin C, Meissner G, Mullakandov M, et al. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord. 2001;11(6-7):530-7. [view publication]
  • Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama. 2001;286(18):2239-44. [view publication]
  • Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001;16(1):114-8. [view publication]
  • Swoboda KJ, Soong BW, McKenna C, Brunt ER, Litt M, Bale JF, et al. Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. Neurology. 2001;57(11 Suppl 4):S42-8. [view publication]
  • Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001;24(5):247-53. [view publication]
  • Tan EK, Jankovic J. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001;13(3):380-4. [view publication]
  • Tan EK, Nagamitsu S, Matsuura T, Khajavi M, Jankovic J, Ondo W, et al. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001;305(1):70-2. [view publication]
  • Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001;2(12):1985-94. [view publication]
  • Tintner R, Jankovic J. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep. 2001;1(4):337-45. [view publication]
  • Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16(2):252-7. [view publication]
  • Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord. 2001;7(2):115-120. [view publication]
  • Xu P, Liang X, Jankovic J, Le W. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001;58(11):1879-82. [view publication]
  • Yoshor D, Hamilton WJ, Ondo W, Jankovic J, Grossman RG. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001;48(4):818-24; discussion 824-6. [view publication]
  • Bain P, Brin M, Deuschl G, Elble R, Jankovic J, Findley L, et al. Criteria for the diagnosis of essential tremor. Neurology. 2000;54(11 Suppl 4):S7. [view publication]
  • Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000;55(12 Suppl 5):S15-21. [view publication]
  • Hallett M, Litvan I, Task Force on Surgery for Parkinson's Disease of the American Academy of Neurology Therapeutic and Technology Assessment Committee. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. Mov Disord. 2000;15(3):436-8. [view publication]
  • Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, Adler RL. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology. 2000;55(9):1364-7. [view publication]
  • Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57(3):369-72. [view publication]
  • Jankovic J. Atypical and typical cranial dystonia following dental procedures. Mov Disord. 2000;15(2):366. [view publication]
  • Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S2-6. [view publication]
  • Jankovic J. Essential tremor: clinical characteristics. Neurology. 2000;54(11 Suppl 4):S21-5. [view publication]
  • Jankovic J. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000;23(5):252-61. [view publication]
  • Kwak C, Jankovic J. Tics in Tourette syndrome and botulinum toxin. J Child Neurol. 2000;15(9):631-4. [view publication]
  • Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57(8):1190-3. [view publication]
  • Lai EC, Jankovic J, Krauss JK, Ondo WG, Grossman RG. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000;55(8):1218-22. [view publication]
  • Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm. 2000;107(10):1165-73. [view publication]
  • Litvan I, Dickson DW, Buttner-Ennever JA, Delacourte A, Hutton M, Dubois B, et al. Research goals in progressive supranuclear palsy. Mov Disord. 2000;15(3):446-58. [view publication]
  • Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington's disease. Neurology. 2000;54(2):452-8. [view publication]
  • Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678-82. [view publication]
  • Ondo W, Warrior D, Overby A, Calmes J, Hendersen N, Olson S, et al. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000;57(10):1464-9. [view publication]
  • Ondo WG, Ben-Aire L, Jankovic J, Lai E, Contant C, Grossman R. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000;101(2):79-84. [view publication]
  • Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord. 2000;6(4):237-240. [view publication]
  • Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Jama. 2000;284(15):1931-8. [view publication]
  • Rettig GM, York MK, Lai EC, Jankovic J, Krauss JK, Grossman RG, et al. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69(3):326-36. [view publication]
  • Ringman JM, Jankovic J. Occurrence of tics in Asperger's syndrome and autistic disorder. J Child Neurol. 2000;15(6):394-400. [view publication]
  • Roberts-Warrior D, Overby A, Jankovic J, Olson S, Lai EC, Krauss JK, et al. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000;123 ( Pt 10):2141-9. [view publication]
  • Swoboda KJ, Soong B, McKenna C, Brunt ER, Litt M, Bale JF, et al. Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology. 2000;55(2):224-30. [view publication]
  • Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. Mov Disord. 2000;15(1):171-3. [view publication]
  • Tan EK, Jankovic J. Hemifacial spasm and hypertension: how strong is the association? Mov Disord. 2000;15(2):363-5. [view publication]
  • Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68(2):186-90. [view publication]
  • Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131(2):211-6. [view publication]
  • Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000;55(4):533-8. [view publication]
  • Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000;54(5):1195-8. [view publication]
  • Uc EY, Wenger DA, Jankovic J. Niemann-Pick disease type C: two cases and an update. Mov Disord. 2000;15(6):1199-203. [view publication]
  • Vanek ZF, Jankovic J. Dystonia in corticobasal degeneration. Adv Neurol. 2000;82:61-7. [view publication]
  • Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000;281(2-3):167-70. [view publication]
  • Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-8. [view publication]
  • Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology. 1999;52(5):907-10. [view publication]
  • Gelb DJ, Oliver E, Gilman S, NINDS Advisory Council. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-9. [view publication]
  • Hallett M, Litvan I, Task Force on Surgery for Parkinson's Disease. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1999;53(9):1910-21. [view publication]
  • Hanna PA, Janjua FN, Contant CF, Jankovic J. Bilineal transmission in Tourette syndrome. Neurology. 1999;53(4):813-8. [view publication]
  • Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999;56(1):90-4. [view publication]
  • Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999;66(5):612-6. [view publication]
  • Jankovic J, Ben-Arie L, Schwartz K, Chen K, Khan M, Lai EC, et al. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999;14(1):57-62. [view publication]
  • Jankovic J, Lai E, Ben-Arie L, Krauss JK, Grossman R. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999;167(1):62-7. [view publication]
  • Jankovic J, Lai EC, Krauss J, Grossman R. Surgical treatment of levodopa-induced dyskinesias. Adv Neurol. 1999;80:603-9. [view publication]
  • Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67(5):646-50. [view publication]
  • Jankovic J. New and emerging therapies for Parkinson disease. Arch Neurol. 1999;56(7):785-90. [view publication]
  • Le W, Conneely OM, He Y, Jankovic J, Appel SH. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999;73(5):2218-21. [view publication]
  • Le W, Conneely OM, Zou L, He Y, Saucedo-Cardenas O, Jankovic J, et al. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999;159(2):451-8. [view publication]
  • Le WD, Rowe DB, Jankovic J, Xie W, Appel SH. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999;56(2):194-200. [view publication]
  • Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246 Suppl 2:II1-5. [view publication]
  • Mathew SJ, Yudofsky SC, McCullough LB, Teasdale TA, Jankovic J. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999;11(2):259-67. [view publication]
  • Miller CS, Gammage RB, Jankovic JT. Exacerbation of chemical sensitivity: a case study. Toxicol Ind Health. 1999;15(3-4):398-402. [view publication]
  • Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999;22(1):1-4. [view publication]
  • Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999;14(4):664-8. [view publication]
  • Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279-81. [view publication]
  • Scott WK, Yamaoka LH, Stajich JM, Scott BL, Vance JM, Roses AD, et al. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999;2(3):191-2. [view publication]
  • Stanley RK, Protas EJ, Jankovic J. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999;31(6):761-6. [view publication]
  • Tan EK, Jankovic J. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999;14(2):345-9. [view publication]
  • Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53(9):2102-7. [view publication]
  • Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. Jama. 1999;281(4):341-6. [view publication]
  • Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999;17(3):196-201. [view publication]
  • Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56(1):98-102. [view publication]
  • Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999;64(15):1275-85. [view publication]
  • Desaloms JM, Krauss JK, Lai EC, Jankovic J, Grossman RG. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998;89(2):194-9. [view publication]
  • Deuschl G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;13 Suppl 3:2-23. [view publication]
  • Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998;50(6):1624-9. [view publication]
  • Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord. 1998;13(6):972-7. [view publication]
  • Jankovic J, Sekula S. Dermatological manifestations of Tourette syndrome and obsessive-compulsive disorder. Arch Dermatol. 1998;134(1):113-4. [view publication]
  • Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol. 1998;78:169-83. [view publication]
  • Jankovic J. Re-emergence of surgery for dystonia. J Neurol Neurosurg Psychiatry. 1998;65(4):434. [view publication]
  • Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A, et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm. 1998;105(2-3):217-27. [view publication]
  • Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55(7):969-78. [view publication]
  • Litvan II, Jankovic J, Goetz CG, Wenning GK, Sastry N, Jellinger K, et al. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. Eur J Neurol. 1998;5(5):451-457. [view publication]
  • Ondo W, Jankovic J, Schwartz K, Almaguer M, Simpson RK. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998;51(4):1063-9. [view publication]
  • Ondo WG, Desaloms JM, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov Disord. 1998;13(4):693-8. [view publication]
  • Ondo WG, Jankovic J, Lai EC, Sankhla C, Khan M, Ben-Arie L, et al. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998;50(1):266-70. [view publication]
  • Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol. 1998;43(3):318-25. [view publication]
  • Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, et al. Decreased [18F]spiperone binding in putamen in dystonia. Adv Neurol. 1998;78:161-8. [view publication]
  • Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998;13(1):150-4. [view publication]
  • Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998;65(5):722-8. [view publication]
  • Scarano VR, Jankovic J. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998;43(2):334-9. [view publication]
  • Shoulson I, Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Ann Neurol. 1998;44(3 Suppl 1):S160-6. [view publication]
  • Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998;21(12):1740-7. [view publication]
  • Wang WW, Khajavi M, Patel BJ, Beach J, Jankovic J, Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998;55(12):1521-3. [view publication]
  • Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64(2):184-9. [view publication]
  • Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am. 1997;20(4):821-38. [view publication]
  • Jankovic J, Beach J, Pandolfo M, Patel PI. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997;54(3):289-94. [view publication]
  • Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358-62. [view publication]
  • Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997;6:S129-45. [view publication]
  • Jankovic J, Hamilton WJ, Grossman RG. Thalamic surgery for movement disorders. Adv Neurol. 1997;74:221-33. [view publication]
  • Jankovic J, Ruzicka E. [Tics and Tourette's syndrome]. Cas Lek Cesk. 1997;136(13):399-404. [view publication]
  • Jankovic J, Scott BL, Evans RW. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1997;12(5):818. [view publication]
  • Jankovic J. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997;15(2):267-75. [view publication]
  • Krauss JK, Desaloms JM, Lai EC, King DE, Jankovic J, Grossman RG. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997;87(3):358-67. [view publication]
  • Krauss JK, Grossman RG, Jankovic J. Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997;12(1):124-6. [view publication]
  • Krauss JK, Grossman RG, Lai EC, Schwartz K, Jankovic J. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997;58(4):153-62. [view publication]
  • Krauss JK, Jankovic J, Lai EC, Rettig GM, Grossman RG. Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997;54(8):1026-9. [view publication]
  • Krauss JK, Jankovic J. Hemidystonia secondary to carotid artery gunshot injury. Childs Nerv Syst. 1997;13(5):285-8. [view publication]
  • Krauss JK, Jankovic J. Tics secondary to craniocerebral trauma. Mov Disord. 1997;12(5):776-82. [view publication]
  • Krauss JK, Seeger W, Jankovic J. Cervical dystonia associated with tumors of the posterior fossa. Mov Disord. 1997;12(3):443-7. [view publication]
  • Krauss JK, Toups EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997;63(5):642-8. [view publication]
  • Le W, Jankovic J, Xie W, Kong R, Appel SH. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett. 1997;224(3):197-200. [view publication]
  • Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701-7. [view publication]
  • Lieberman A, Ranhosky A, Korts D, Pramipexole Study Group Investigators. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162-8. [view publication]
  • Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48(1):119-25. [view publication]
  • Litvan I, Agid Y, Sastry N, Jankovic J, Wenning GK, Goetz CG, et al. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology. 1997;49(1):62-9. [view publication]
  • Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997;54(8):937-44. [view publication]
  • Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA, Midodrine Study Group. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Jama. 1997;277(13):1046-51. [view publication]
  • Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42(5):747-55. [view publication]
  • Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997;17(2):843-50. [view publication]
  • Scott WK, Staijich JM, Yamaoka LH, Speer MC, Vance JM, Roses AD, et al. Genetic complexity and Parkinson's disease. Science. 1997;277(5324):387-8; author reply 389. [view publication]
  • Alford RL, Ashizawa T, Jankovic J, Caskey CT, Richards CS. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996;66(3):281-6. [view publication]
  • Ashizawa T, Jankovic J. Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996;11(4):457-9. [view publication]
  • Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996;46(5):1470. [view publication]
  • Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19(2):157-64. [view publication]
  • Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology. 1996;46(4):1040-3. [view publication]
  • Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology. 1996;46(4):965-8. [view publication]
  • Hallett M, Daroff RB, Benign Essential Blepharospasm Research Foundation. Blepharospasm: report of a workshop. Neurology. 1996;46(5):1213-8. [view publication]
  • Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11(3):250-6. [view publication]
  • Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry. 1996;60(6):704. [view publication]
  • Krauss JK, Akeyson EW, Giam P, Jankovic J. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996;83(2):420-22. [view publication]
  • Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996;11(5):563-6. [view publication]
  • Krauss JK, Jankovic J. Surgical treatment of Parkinson's disease. Am Fam Physician. 1996;54(5):1621-9. [view publication]
  • Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. [view publication]
  • Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46(4):922-30. [view publication]
  • Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: differentiation from Alzheimer's disease. Neurology. 1996;46(3):720-6. [view publication]
  • Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47(6):1435-41. [view publication]
  • Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39(1):37-45. [view publication]
  • Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39(1):29-36. [view publication]
  • Protas EJ, Stanley RK, Jankovic J, MacNeill B. Cardiovascular and metabolic responses to upper- and lower-extremity exercise in men with idiopathic Parkinson's disease. Phys Ther. 1996;76(1):34-40. [view publication]
  • Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1996;11(6):748-51. [view publication]
  • Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996;11(4):431-3. [view publication]
  • Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996;46(1):68-74. [view publication]
  • Cardoso F, Jankovic J, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995;36(3):501-7; discussion 507-8. [view publication]
  • Cardoso F, Jankovic J. Clinical use of botulinum neurotoxins. Curr Top Microbiol Immunol. 1995;195:123-41. [view publication]
  • Cardoso F, Jankovic J. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995;52(3):263-70. [view publication]
  • Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7(4):471-5. [view publication]
  • Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995;38(4):571-9. [view publication]
  • Jankovic J, Ashizawa T. Tourettism associated with Huntington's disease. Mov Disord. 1995;10(1):103-5. [view publication]
  • Jankovic J, Beach J, Ashizawa T. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995;32(7):516-8. [view publication]
  • Jankovic J, Beach J, Schwartz K, Contant C. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995;45(4):645-8. [view publication]
  • Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995;37(4):680-6; discussion 686-7. [view publication]
  • Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45(9):1743-6. [view publication]
  • Jankovic J. Apraxia of lid opening. Mov Disord. 1995;10(5):686-7. [view publication]
  • Jankovic J. International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord. 1995;10(5):533-40. [view publication]
  • Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18(3):197-214. [view publication]
  • McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995;52(6):565-70. [view publication]
  • Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol. 1995;52(3):237-45. [view publication]
  • Shulman LM, Lang AE, Jankovic J, David NJ, Weiner WJ. Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. Mov Disord. 1995;10(3):257-62. [view publication]
  • Ashizawa T, Wong LJ, Richards CS, Caskey CT, Jankovic J. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994;44(6):1137-43. [view publication]
  • Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem. 1994;62(4):1631-4. [view publication]
  • Jankovic J, Shoulson I, Weiner WJ. Early-stage Parkinson's disease: to treat or not to treat. Neurology. 1994;44(3 Suppl 1):S4-7. [view publication]
  • Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol. 1994;7(4):358-66. [view publication]
  • Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994;9(3):347-9. [view publication]
  • Jankovic J. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994;44(11):2006-14. [view publication]
  • Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9(1):40-7. [view publication]
  • Percy AK, Glaze DG, Schultz RJ, Zoghbi HY, Williamson D, Frost JD, et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35(4):464-70. [view publication]
  • Piwinski SE, Jankovic J, McElligott MA. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994;34(5):466-71. [view publication]
  • Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Neurology. 1994;44(12):2401-3. [view publication]
  • Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:189-201. [view publication]
  • Wojcieszek J, Lang AE, Jankovic J, Greene P, Deck J. What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. Mov Disord. 1994;9(3):358-66. [view publication]
  • Cardoso F, Jankovic J. Movement disorders. Neurol Clin. 1993;11(3):625-38. [view publication]
  • Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord. 1993;8(2):175-8. [view publication]
  • Cardoso FE, Jankovic J. Hereditary motor-sensory neuropathy and movement disorders. Muscle Nerve. 1993;16(9):904-10. [view publication]
  • Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci. 1993;5(2):206-8. [view publication]
  • Jankovic J, Contant C, Perlmutter J. Essential tremor and PD. Neurology. 1993;43(7):1447-9. [view publication]
  • Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38-48. [view publication]
  • Jankovic J, Rajput AH, Golbe LI, Goodman JC. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993;8(4):525-32. [view publication]
  • Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993;43(4):834-6. [view publication]
  • Jankovic J, Schwartz KS. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg [Am]. 1993;18(5):883-7. [view publication]
  • Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol. 1993;50(3):286-8. [view publication]
  • Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993;43(2):349-52. [view publication]
  • Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann Neurol. 1993;33(4):350-6. [view publication]
  • Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328(3):176-83. [view publication]
  • Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993;43(5):937-41. [view publication]
  • Stacy M, Jankovic J. Childhood dystonia. Pediatr Ann. 1993;22(1):53-8. [view publication]
  • Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Annu Rev Med. 1993;44:431-40. [view publication]
  • Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol. 1993;50(10):1013-6. [view publication]
  • Burnett L, Jankovic J. Chorea and ballism. Curr Opin Neurol Neurosurg. 1992;5(3):308-13. [view publication]
  • Doody RS, Jankovic J. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992;55(9):806-10. [view publication]
  • Friedman DI, Jankovic J, McCrary JA, 3rd. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol. 1992;12(2):104-9. [view publication]
  • Jankovic J, Wooten M, Van der Linden C, Jansson B. Low body weight in Parkinson's disease. South Med J. 1992;85(4):351-4. [view publication]
  • Jankovic J. Diagnosis and classification of tics and Tourette syndrome. Adv Neurol. 1992;58:7-14. [view publication]
  • Lew H, Jordan C, Jerger J, Jankovic J. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992;42(3 Pt 1):594-7. [view publication]
  • Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord. 1992;7(1):62-3. [view publication]
  • Shoulson I, Parkinson Study Group. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. Eur Neurol. 1992;32 Suppl 1:46-53. [view publication]
  • Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurol Clin. 1992;10(2):341-59. [view publication]
  • Stacy M, Jankovic J. Tardive tremor. Mov Disord. 1992;7(1):53-7. [view publication]
  • Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991;6(1):12-20. [view publication]
  • FitzGerald PM, Jankovic J. Orthostatic tremor: an association with essential tremor. Mov Disord. 1991;6(1):60-4. [view publication]
  • Goetz CG, Stebbins GT, 3rd, Klawans HL, Koller WC, Grossman RG, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991;41(11):1719-22. [view publication]
  • Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324(17):1186-94. [view publication]
  • Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41(7):1088-91. [view publication]
  • Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology. 1991;41(8):1185-8. [view publication]
  • Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991;48(12):1253-6. [view publication]
  • Jankovic J, Stone L. Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991;6(3):248-52. [view publication]
  • LeWitt PA, Parkinson Study Group. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. Acta Neurol Scand Suppl. 1991;136:79-86. [view publication]
  • Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology. 1991;41(2 ( Pt 1)):234-8. [view publication]
  • Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal baclofen for intractable axial dystonia. Neurology. 1991;41(7):1141-2. [view publication]
  • Narayana PA, Slopis JM, Jackson EF, Jankovic J, Butler IJ. Proton magnetic resonance spectroscopic studies of hypertrophied muscle. Effect of botulinum toxin treatment. Invest Radiol. 1991;26(1):58-64. [view publication]
  • National Institutes of Health Consensus Development Conference Statement. Clinical use of botulinum toxin. Arch Neurol. 1991;48(12):1294-8. [view publication]
  • Parkinson Study Group. DATATOP and clinical neuromythology IX. Neurology. 1991;41(6):771-7. [view publication]
  • Stone LA, Jankovic J. The coexistence of tics and dystonia. Arch Neurol. 1991;48(8):862-5. [view publication]
  • Taylor LD, Krizman DB, Jankovic J, Hayani A, Steuber PC, Greenberg F, et al. 9p monosomy in a patient with Gilles de la Tourette's syndrome. Neurology. 1991;41(9):1513-5. [view publication]
  • Carter JB, Patrinely JR, Jankovic J, McCrary JA, 3rd, Boniuk M. Familial hemifacial spasm. Arch Ophthalmol. 1990;108(2):249-50. [view publication]
  • FitzGerald PM, Jankovic J, Glaze DG, Schultz R, Percy AK. Extrapyramidal involvement in Rett's syndrome. Neurology. 1990;40(2):293-5. [view publication]
  • FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5(3):195-202. [view publication]
  • Jankovic J, Friedman DI, Pirozzolo FJ, McCrary JA. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990;53:293-304. [view publication]
  • Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40(10):1529-34. [view publication]
  • Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53(8):633-9. [view publication]
  • Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40(2):277-80. [view publication]
  • Jankovic J. Lower body (vascular) parkinsonism. Arch Neurol. 1990;47(7):728. [view publication]
  • Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83(5):525-32. [view publication]
  • Miller LG, Jankovic J. Sulpiride-induced tardive dystonia. Mov Disord. 1990;5(1):83-4. [view publication]
  • Persing JA, Muir A, Becker DG, Jankovic JJ, Anderson RL, Edlich RF. Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. J Emerg Med. 1990;8(5):571-4. [view publication]
  • Beall SS, Patten BM, Mallette L, Jankovic J. Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. Ann Neurol. 1989;26(4):569-75. [view publication]
  • Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4(2):157-75. [view publication]
  • Dewey RB, Jr, Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989;46(8):862-7. [view publication]
  • FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4(3):249-60. [view publication]
  • FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology. 1989;39(11):1434-7. [view publication]
  • Jankovic J, Grossman R, Goodman C, Pirozzolo F, Schneider L, Zhu Z, et al. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989;39(9):1227-34. [view publication]
  • Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989;4(4):303-9. [view publication]
  • Jankovic J, Shale H. Dystonia in musicians. Semin Neurol. 1989;9(2):131-5. [view publication]
  • Jankovic J. Essential tremor and Parkinson's disease. Ann Neurol. 1989;25(2):211-2. [view publication]
  • Jankovic J. Parkinsonism-plus syndromes. Mov Disord. 1989;4 Suppl 1:S95-119. [view publication]
  • Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989;149(11):2486-92. [view publication]
  • Nath A, Jankovic J. Motor disorders in patients with human immunodeficiency virus infection. Prog AIDS Pathol. 1989;1:159-66. [view publication]
  • Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46(10):1052-60. [view publication]
  • Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321(20):1364-71. [view publication]
  • Shoulson I, Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurol Scand Suppl. 1989;126:171-5. [view publication]
  • Jankovic J, Armstrong D, Low NL, Goetz CG. Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988;3(4):352-61. [view publication]
  • Jankovic J, Armstrong D, Low NL, Rapin I. Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. Mov Disord. 1988;3(4):362-9. [view publication]
  • Jankovic J, Caskey TC, Stout JT, Butler IJ. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988;23(5):466-9. [view publication]
  • Jankovic J, Nutt JG. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988;49:117-23. [view publication]
  • Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38(3):391-4. [view publication]
  • Jankovic J, Van der Linden C. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988;51(12):1512-9. [view publication]
  • Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988;50:583-91. [view publication]
  • Jankovic J. Botulinum A toxin in the treatment of blepharospasm. Adv Neurol. 1988;49:467-72. [view publication]
  • Jankovic J. Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988;49:1-13. [view publication]
  • Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988;49:103-16. [view publication]
  • Jankovic J. Hemiparkinsonism and hemiatrophy. Neurology. 1988;38(11):1815-6. [view publication]
  • Jankovic J. Orofacial and other self-mutilations. Adv Neurol. 1988;49:365-81. [view publication]
  • Jankovic J. Parkinson's disease: recent advances in therapy. South Med J. 1988;81(8):1021-7. [view publication]
  • Percy AK, Zoghbi HY, Lewis KR, Jankovic J. Rett syndrome: qualitative and quantitative differentiation from autism. J Child Neurol. 1988;3 Suppl:S65-7. [view publication]
  • Rosenbaum F, Jankovic J. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988;38(4):522-7. [view publication]
  • Singh SK, Jankovic J. Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988;3(3):274-80. [view publication]
  • Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology. 1987;37(4):570-6. [view publication]
  • Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987;10(6):511-21. [view publication]
  • Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37(4):616-23. [view publication]
  • Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol. 1987;45:551-4. [view publication]
  • Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord. 1987;2(3):159-63. [view publication]
  • Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987;14(3 Suppl):541-6. [view publication]
  • Koller W, O'Hara R, Weiner W, Lang A, Nutt J, Agid Y, et al. Relationship of aging to Parkinson's disease. Adv Neurol. 1987;45:317-21. [view publication]
  • Kurlan R, Jankovic J, Rubin A, Patten B, Griggs R, Shoulson I. Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? Arch Neurol. 1987;44(10):1057-60. [view publication]
  • Little JT, Jankovic J. Tardive myoclonus. Mov Disord. 1987;2(4):307-11. [view publication]
  • Miller RH, Woodson GE, Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg. 1987;113(6):603-5. [view publication]
  • Nath A, Jankovic J, Pettigrew LC. Movement disorders and AIDS. Neurology. 1987;37(1):37-41. [view publication]
  • Friedman DI, Jankovic J, Rolak LA. Arteriovenous malformation presenting as hemidystonia. Neurology. 1986;36(12):1590-3. [view publication]
  • Gospe SM, Jr, Jankovic J. Drug-induced dystonia in neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1986;2(4):236-7. [view publication]
  • Inbody S, Jankovic J. Hyperkinetic mutism: bilateral ballism and basal ganglia calcification. Neurology. 1986;36(6):825-7. [view publication]
  • Jankovic J, Fahn S. The phenomenology of tics. Mov Disord. 1986;1(1):17-26. [view publication]
  • Jankovic J, Newmark M, Peter P. Parkinsonism and acquired hydrocephalus. Mov Disord. 1986;1(1):59-64. [view publication]
  • Jankovic J, Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology. 1986;36(2):303-4. [view publication]
  • Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol. 1986;43(10):1025-31. [view publication]
  • Jankovic J, Reches A. Parkinson's disease in monozygotic twins. Ann Neurol. 1986;19(4):405-8. [view publication]
  • Jankovic J. Blepharospasm with basal ganglia lesions. Arch Neurol. 1986;43(9):866-8. [view publication]
  • Jankovic J. Myoglobinuric renal failure in Huntington's chorea. Neurology. 1986;36(1):138-9. [view publication]
  • Jankovic J. Recent advances in the management of tics. Clin Neuropharmacol. 1986;9 Suppl 2:S100-10. [view publication]
  • Jankovic J. Whipple's disease of the central nervous system in AIDS. N Engl J Med. 1986;315(16):1029-30. [view publication]
  • Wells CR, Jankovic J. Familial spastic paraparesis and deafness. A new x-linked neurodegenerative disorder. Arch Neurol. 1986;43(9):943-6. [view publication]
  • Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol. 1985;17(4):329-33. [view publication]
  • Jankovic J, Glass JP. Metoclopramide-induced phantom dyskinesia. Neurology. 1985;35(3):432-5. [view publication]
  • Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology. 1985;35(2):227-34. [view publication]
  • Jankovic J, Orman J, Jansson B. Placebo-controlled study of mesulergine in Parkinson's disease. Neurology. 1985;35(2):161-5. [view publication]
  • Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology. 1985;35(3):296-9. [view publication]
  • Jankovic J. Long-term use of dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 1985;8(2):131-40. [view publication]
  • Jankovic J. Progressive supranuclear palsy: paraneoplastic effect of bronchial carcinoma. Neurology. 1985;35(3):446-7. [view publication]
  • Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol. 1985;17(5):505-9. [view publication]
  • Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry. 1985;48(7):650-7. [view publication]
  • Reshef E, Greenberg SB, Jankovic J. Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. J Neurol Neurosurg Psychiatry. 1985;48(2):122-7. [view publication]
  • Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985;35(3):366-70. [view publication]
  • Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology. 1985;35(4):522-6. [view publication]
  • Zetusky WJ, Jankovic J. Laterality and symptom association in Parkinson's disease. Arch Neurol. 1985;42(12):1132-3. [view publication]
  • Fahn S, Jankovic J. Practical management of dystonia. Neurol Clin. 1984;2(3):555-69. [view publication]
  • Glass JP, Jankovic J, Borit A. Hemiballism and metastatic brain tumor. Neurology. 1984;34(2):204-7. [view publication]
  • Jankovic J, Glaze DG, Frost JD, Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology. 1984;34(5):688-92. [view publication]
  • Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. 1984;16(4):371-6. [view publication]
  • Jankovic J. Progressive supranuclear palsy. Clinical and pharmacologic update. Neurol Clin. 1984;2(3):473-86. [view publication]
  • Evans BK, Jankovic J. Tuberous sclerosis and chorea. Ann Neurol. 1983;13(1):106-7. [view publication]
  • Glaze DG, Frost JD, Jr, Jankovic J. Sleep in Gilles de la Tourette's syndrome: disorder of arousal. Neurology. 1983;33(5):586-92. [view publication]
  • Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13(3):273-8. [view publication]
  • Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol. 1983;13(4):402-11. [view publication]
  • Jankovic J, Patel SC. Blepharospasm associated with brainstem lesions. Neurology. 1983;33(9):1237-40. [view publication]
  • Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology. 1983;33(4):505-7. [view publication]
  • Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol. 1983;37:277-89. [view publication]
  • Levy RS, Jankovic J. Placebo-induced conversion reaction: a neurobehavioral and EEG study of hysterical aphasia, seizure, and coma. J Abnorm Psychol. 1983;92(2):243-9. [view publication]
  • Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia and inappropriate use of neuroleptic drugs. Lancet. 1982;1(8284):1299. [view publication]
  • Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. [view publication]
  • Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. Jama. 1982;248(23):3160-4. [view publication]
  • Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology. 1982;32(10):1195-7. [view publication]
  • Jankovic J. Management of motor side effects of chronic levodopa therapy. Clin Neuropharmacol. 1982;5 Suppl 1:S19-28. [view publication]
  • Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11(1):41-7. [view publication]
  • Jankovic J, Frost JD, Jr. Quantitative assessment of parkinsonian and essential tremor: clinical application of triaxial accelerometry. Neurology. 1981;31(10):1235-40. [view publication]
  • Jankovic J. Drug-induced and other orofacial-cervical dyskinesias. Ann Intern Med. 1981;94(6):788-93. [view publication]
  • Jankovic J. L-dopa-resistant parkinsonism due to dopa decarboxylase deficiency? Ann Neurol. 1981;10(1):64-5. [view publication]
  • Porter M, Jankovic J. Benign coital cephalalgia. Differential diagnosis and treatment. Arch Neurol. 1981;38(11):710-2. [view publication]
  • Ashizawa T, Patten BM, Jankovic J. Meige's syndrome. South Med J. 1980;73(7):863-6. [view publication]
  • Jankovic J, Derman H, Armstrong D. Haemorrhagic complications of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1980;43(1):76-81. [view publication]
  • Jankovic J, Fahn S. Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med. 1980;93(3):460-5. [view publication]
  • Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979;6(3):227-31. [view publication]
  • Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: a new syndrome. Trans Am Neurol Assoc. 1978;103:116-8. [view publication]

E-mail this page to a friend